<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33690729</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS One</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line.</ArticleTitle>
        <Pagination>
          <StartPage>e0248103</StartPage>
          <MedlinePgn>e0248103</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e0248103</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0248103</ELocationID>
        <Abstract>
          <AbstractText>The incidence of endometrial cancer (EC) has increased over the past years and mainly affects women above the age of 45 years. Metabolic diseases such as obesity and type II diabetes mellitus as well as associated conditions like polycystic ovary syndrome (PCOS), insulin resistance and hyperinsulinemia lead to elevated levels of circulating estrogens. Increased estrogen concentrations, in turn, further trigger the proliferation of endometrial cells and thus promote EC development and progression, especially in the absence of progesterone as seen in postmenopausal women. Elevated blood glucose levels in diabetic patients further contribute to the risk of EC development. Metformin is an insulin-sensitizing biguanide drug, commonly used in the treatment of type II diabetes mellitus, especially in obese patients. Besides its effects on glucose metabolism, metformin displayed anti-cancer effects in various cancer types, including EC. Direct anti-cancer effects of metformin target signaling pathways that are involved in cellular growth and proliferation, e.g. the AKT/PKB/mTOR pathway. Further proteins and pathways have been suggested as potential targets, but the underlying mechanism of action of metformin's anti-cancer activity is still not completely understood. In the present study, the effects of metformin on protein expression were investigated in the human EC cell line HEC-1A using an affinity proteomic approach. Cells were treated with 0.5 mmol/L metformin over a period of 7 days and changes in the expression pattern of 1,300 different proteins were compared to the expression in untreated control cells as well as insulin-treated cells. Insulin treatment (100 ng/mL) was incorporated into the study in order to implement a model for insulin resistance and associated hyperinsulinemia, conditions that are often observed in obese and diabetic patients. Furthermore, the culture medium was supplemented with 10 nmol/L ß-estradiol (E2) during treatments to mimic increased estrogen levels, a common risk factor for EC development. Based on the most prominent and significant changes in expression, a set of 80 proteins was selected and subjected to a more detailed analysis. The data revealed that metformin and insulin targeted similar pathways in the present study and mostly acted on proteins related to proliferation, migration and tumor immune response. These pathways may be affected in a tumor-promoting as well as a tumor-suppressing way by either metformin treatment or insulin supplementation. The consequences for the cells resulting from the detected expression changes were discussed in detail for several proteins. The presented data helps identify potential targets affected by metformin treatment in EC and allows for a better understanding of the mechanism of action of the biguanide drug's anti-cancer activity. However, further investigations are necessary to confirm the observations and conclusions drawn from the presented data after metformin administration, especially for proteins that were regulated in a favorable way, i.e. AKT3, CCND2, CD63, CD81, GFAP, IL5, IL17A, IRF4, PI3, and VTCN1. Further proteins might be of interest, where metformin counteracted unfavorable effects that have been induced by hyperinsulinemia.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lange</LastName>
            <ForeName>Carsten</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0003-4915-0870</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gynecologic Endocrinology and Fertility Disorders, Women's Hospital, Ruprecht-Karls University of Heidelberg, Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Machado Weber</LastName>
            <ForeName>Amanda</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecologic Endocrinology and Fertility Disorders, Women's Hospital, Ruprecht-Karls University of Heidelberg, Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schmidt</LastName>
            <ForeName>Ronny</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Sciomics GmbH, Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schroeder</LastName>
            <ForeName>Christoph</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-6177-1042</Identifier>
            <AffiliationInfo>
              <Affiliation>Sciomics GmbH, Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strowitzki</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecologic Endocrinology and Fertility Disorders, Women's Hospital, Ruprecht-Karls University of Heidelberg, Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Germeyer</LastName>
            <ForeName>Ariane</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecologic Endocrinology and Fertility Disorders, Women's Hospital, Ruprecht-Karls University of Heidelberg, Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9100L32L2N</RegistryNumber>
          <NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006946" MajorTopicYN="N">Hyperinsulinism</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors have read the journal’s policy and have the following competing interests to declare: R.S. is a paid employee of Sciomics GmbH, C.S. is founder and shareholder of Sciomics GmbH. There are no patents, products in development or marketed products to declare based on the data presented. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>18</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33690729</ArticleId>
        <ArticleId IdType="pmc">PMC7943011</ArticleId>
        <ArticleId IdType="doi">10.1371/journal.pone.0248103</ArticleId>
        <ArticleId IdType="pii">PONE-D-20-26246</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016; 387(10023): 1094–108. 10.1016/S0140-6736(15)00130-0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(15)00130-0</ArticleId>
            <ArticleId IdType="pubmed">26354523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. Int J Gynecol Obstet. 2018; 143(Suppl 2): 37–50. 10.1002/ijgo.12612
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijgo.12612</ArticleId>
            <ArticleId IdType="pubmed">30306580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garg K, Soslow RA. Endometrial carcinoma in women aged 40 years and younger. Archives of Pathology &amp; Laboratory Medicine. 2014; 138(3): 335–42. 10.5858/arpa.2012-0654-RA
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5858/arpa.2012-0654-RA</ArticleId>
            <ArticleId IdType="pubmed">24576029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrne FL, Poon IK, Modesitt SC, Tomsig JL, Chow JD, Healy ME, et al.. Metabolic vulnerabilities in endometrial cancer. Cancer Res. 2014; 74(20): 5832–45. 10.1158/0008-5472.CAN-14-0254
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-0254</ArticleId>
            <ArticleId IdType="pubmed">25205105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Cancer Society. Key statistics for endometrial cancer 2020 [accessed 2020 Aug 18]; available from: https://www.cancer.org/cancer/endometrial-cancer/about/key-statistics.html#references.</Citation>
        </Reference>
        <Reference>
          <Citation>Collins G, Mesiano S, DiFeo A. Effects of metformin on cellular proliferation and steroid hormone receptors in patient-derived, low-grade endometrial cancer cell lines. Reprod Sci. 2019; 26(5): 609–18. 10.1177/1933719118779734
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1933719118779734</ArticleId>
            <ArticleId IdType="pubmed">29848180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Cancer Society. Endometrial cancer causes, risk factors, and prevention: American Cancer Society; 2019.  [accessed 2020 Aug 18]; available from: https://www.cancer.org/cancer/endometrial-cancer/causes-risks-prevention.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Szablewski L.
Diabetes mellitus: influences on cancer risk. Diabetes Metab Res Rev. 2014; 30(7): 543–53. 10.1002/dmrr.2573
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dmrr.2573</ArticleId>
            <ArticleId IdType="pubmed">25044584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao R, Li X, Feng Y, Lin JF, Billig H. Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. J Exp Clin Cancer Res. 2014; 33(1): 41. 10.1186/1756-9966-33-41
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-9966-33-41</ArticleId>
            <ArticleId IdType="pmc">PMC4036091</ArticleId>
            <ArticleId IdType="pubmed">24887156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Connor KA, Ferrell RJ, Brindle E, Shofer J, Holman DJ, Miller RC, et al.. Total and unopposed estrogen exposure across stages of the transition to menopause. Cancer Epidemiol Biomarkers Prev. 2009; 18(3): 828–36. 10.1158/1055-9965.EPI-08-0996
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1055-9965.EPI-08-0996</ArticleId>
            <ArticleId IdType="pmc">PMC2675575</ArticleId>
            <ArticleId IdType="pubmed">19240232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev. 1990; 11(2): 266–301. 10.1210/edrv-11-2-266
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/edrv-11-2-266</ArticleId>
            <ArticleId IdType="pubmed">2114281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Modesitt SC, Geffel DL, Via J, A LW. Morbidly obese women with and without endometrial cancer: are there differences in measured physical fitness, body composition, or hormones? Gynecol Oncol. 2012; 124(3): 431–6. 10.1016/j.ygyno.2011.11.013
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2011.11.013</ArticleId>
            <ArticleId IdType="pubmed">22101155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joung KH, Jeong JW, Ku BJ. The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. Biomed Res Int. 2015; 2015: 920618. 10.1155/2015/920618
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/920618</ArticleId>
            <ArticleId IdType="pmc">PMC4383430</ArticleId>
            <ArticleId IdType="pubmed">25866823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flory J, Lipska K. Metformin in 2019. JAMA. 2019; 321(19): 1926–7. 10.1001/jama.2019.3805
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2019.3805</ArticleId>
            <ArticleId IdType="pmc">PMC7552083</ArticleId>
            <ArticleId IdType="pubmed">31009043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dewan S, Wilding J. Adult obesity: metabolic syndrome, diabetes and non‐alcoholic steatohepatitis In: Kopelman PG, Caterson ID, Dietz WH, editors. Clinical Obesity in Adults and Children
2nd ed. Malden (MA): Blackwell Publishing; 2005. p. 249–68. 10.1002/9780470987087</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/9780470987087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meireles CG, Pereira SA, Valadares LP, Rêgo DF, Simeoni LA, Guerra ENS, et al.. Effects of metformin on endometrial cancer: systematic review and meta-analysis. Gynecol Oncol. 2017; 147(1): 167–80. 10.1016/j.ygyno.2017.07.120
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2017.07.120</ArticleId>
            <ArticleId IdType="pubmed">28760367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32(9): 1620–5. 10.2337/dc08-2175
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc08-2175</ArticleId>
            <ArticleId IdType="pmc">PMC2732153</ArticleId>
            <ArticleId IdType="pubmed">19564453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. British Medical Journal. 2005; 330(7503): 1304–5. 10.1136/bmj.38415.708634.F7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.38415.708634.F7</ArticleId>
            <ArticleId IdType="pmc">PMC558205</ArticleId>
            <ArticleId IdType="pubmed">15849206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, et al.. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol. 2014; 132(2): 438–42. 10.1016/j.ygyno.2013.11.021
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2013.11.021</ArticleId>
            <ArticleId IdType="pubmed">24269517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Frimer M, et al.. Metformin use and endometrial cancer survival. Gynecol Oncol. 2014; 132(1): 236–40. 10.1016/j.ygyno.2013.10.026
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2013.10.026</ArticleId>
            <ArticleId IdType="pmc">PMC3904540</ArticleId>
            <ArticleId IdType="pubmed">24189334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012; 35(2): 299–304. 10.2337/dc11-1313
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc11-1313</ArticleId>
            <ArticleId IdType="pmc">PMC3263862</ArticleId>
            <ArticleId IdType="pubmed">22266734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012; 2(9): 778–90. 10.1158/2159-8290.CD-12-0263
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-12-0263</ArticleId>
            <ArticleId IdType="pubmed">22926251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karnevi E, Said K, Andersson R, Rosendahl AH. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer. 2013; 13(1): 235. 10.1186/1471-2407-13-235
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-13-235</ArticleId>
            <ArticleId IdType="pmc">PMC3661399</ArticleId>
            <ArticleId IdType="pubmed">23663483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Wang JL, Ji M, Yuan ZF, Peng Z, Zhang Y, et al.. Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cells. Oncol Lett. 2014; 8(5): 1993–9. 10.3892/ol.2014.2466
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2014.2466</ArticleId>
            <ArticleId IdType="pmc">PMC4186557</ArticleId>
            <ArticleId IdType="pubmed">25289085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pierotti MA, Berrino F, Gariboldi M, Melani C, Mogavero A, Negri T, et al.. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene. 2013; 32(12): 1475–87. 10.1038/onc.2012.181
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2012.181</ArticleId>
            <ArticleId IdType="pubmed">22665053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo H, Kong W, Zhang L, Han J, Clark LH, Yin Y, et al.. Reversal of obesity-driven aggressiveness of endometrial cancer by metformin. Am J Cancer Res. 2019; 9(10): 2170–93. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6834476</ArticleId>
            <ArticleId IdType="pubmed">31720081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daugan M, Dufaÿ Wojcicki A, d’Hayer B, Boudy V. Metformin: an anti-diabetic drug to fight cancer. Pharmacol Res. 2016; 113(Pt. A): 675–85. 10.1016/j.phrs.2016.10.006
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2016.10.006</ArticleId>
            <ArticleId IdType="pubmed">27720766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al.. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447): 67–73. 10.1038/nature12113
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12113</ArticleId>
            <ArticleId IdType="pmc">PMC3704730</ArticleId>
            <ArticleId IdType="pubmed">23636398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weigelt B, Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol. 2012; 24(5): 554–63. 10.1097/CCO.0b013e328354e585
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCO.0b013e328354e585</ArticleId>
            <ArticleId IdType="pubmed">22581357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, et al.. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011; 1(2): 170–85. 10.1158/2159-8290.CD-11-0039
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-11-0039</ArticleId>
            <ArticleId IdType="pmc">PMC3187555</ArticleId>
            <ArticleId IdType="pubmed">21984976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markowska A, Pawałowska M, Filas V, Korski K, Gryboś M, Sajdak S, et al.. Does metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer?
Diabetol Metab Syndr. 2013; 5(1): 76. 10.1186/1758-5996-5-76
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1758-5996-5-76</ArticleId>
            <ArticleId IdType="pmc">PMC4029605</ArticleId>
            <ArticleId IdType="pubmed">24308813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, et al.. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010; 11(5): 390–401. 10.1016/j.cmet.2010.03.014
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2010.03.014</ArticleId>
            <ArticleId IdType="pmc">PMC3081779</ArticleId>
            <ArticleId IdType="pubmed">20444419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2012; 29(2): 1314–27. 10.1007/s12032-011-9846-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12032-011-9846-7</ArticleId>
            <ArticleId IdType="pubmed">21301998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J, Yesilkanal AE, Wynne JP, Frankenberger C, Liu J, Yan J, et al.. Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. Nature. 2019; 568(7751): 254–8. 10.1038/s41586-019-1005-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1005-x</ArticleId>
            <ArticleId IdType="pmc">PMC6698916</ArticleId>
            <ArticleId IdType="pubmed">30842661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vial G, Detaille D, Guigas B. Role of mitochondria in the mechanism(s) of action of metformin. Front Endocrinol (Lausanne).
2019; 10: 294. 10.3389/fendo.2019.00294
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2019.00294</ArticleId>
            <ArticleId IdType="pmc">PMC6514102</ArticleId>
            <ArticleId IdType="pubmed">31133988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saini N, Yang X. Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells. Acta Biochim Biophysica Sin (Shanghai). 2018; 50(2): 133–43. 10.1093/abbs/gmx106
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/abbs/gmx106</ArticleId>
            <ArticleId IdType="pubmed">29342230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, et al.. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012; 11(2): 367–76. 10.4161/cc.11.2.18813
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.11.2.18813</ArticleId>
            <ArticleId IdType="pubmed">22189713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aljofan M, Riethmacher D. Anticancer activity of metformin: a systematic review of the literature. Future Sci OA. 2019; 5(8): FSO410. 10.2144/fsoa-2019-0053
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2144/fsoa-2019-0053</ArticleId>
            <ArticleId IdType="pmc">PMC6745597</ArticleId>
            <ArticleId IdType="pubmed">31534778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tseng HW, Li SC, Tsai KW. Metformin treatment suppresses melanoma cell growth and motility through modulation of microRNA expression. Cancers. 2019; 11(2): 209. 10.3390/cancers11020209
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11020209</ArticleId>
            <ArticleId IdType="pmc">PMC6406940</ArticleId>
            <ArticleId IdType="pubmed">30754729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuramoto H, Tamura S, Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol. 1972; 114(8): 1012–9. 10.1016/0002-9378(72)90861-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0002-9378(72)90861-7</ArticleId>
            <ArticleId IdType="pubmed">4673779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuramoto H, Hamano M, Imai M. HEC-1 cells. Hum Cell. 2002; 15(2): 81–95. 10.1111/j.1749-0774.2002.tb00103.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-0774.2002.tb00103.x</ArticleId>
            <ArticleId IdType="pubmed">12227503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hevir-Kene N, Rižner TL. The endometrial cancer cell lines Ishikawa and HEC-1A, and the control cell line HIEEC, differ in expression of estrogen biosynthetic and metabolic genes, and in androstenedione and estrone-sulfate metabolism. Chem Biol Interact. 2015; 234: 309–19. 10.1016/j.cbi.2014.11.015
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cbi.2014.11.015</ArticleId>
            <ArticleId IdType="pubmed">25437045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med. 2017; 23(7): 804–14. 10.1038/nm.4350
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4350</ArticleId>
            <ArticleId IdType="pmc">PMC6048953</ArticleId>
            <ArticleId IdType="pubmed">28697184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filigheddu N, Sampietro S, Chianale F, Porporato PE, Gaggianesi M, Gregnanin I, et al.. Diacylglycerol kinase α mediates 17-β-estradiol-induced proliferation, motility, and anchorage-independent growth of Hec-1A endometrial cancer cell line through the G protein-coupled estrogen receptor GPR30. Cell Signal. 2011; 23(12): 1988–96. 10.1016/j.cellsig.2011.07.009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2011.07.009</ArticleId>
            <ArticleId IdType="pubmed">21802511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al.. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7): e47. 10.1093/nar/gkv007
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId>
            <ArticleId IdType="pmc">PMC4402510</ArticleId>
            <ArticleId IdType="pubmed">25605792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>Sill M, Schröder C, Hoheisel JD, Benner A, Zucknick M. Assessment and optimisation of normalisation methods for dual-colour antibody microarrays. BMC Bioinformatics. 2010; 11: 556. 10.1186/1471-2105-11-556
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2105-11-556</ArticleId>
            <ArticleId IdType="pmc">PMC3098099</ArticleId>
            <ArticleId IdType="pubmed">21073702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med. 1990; 9(7): 811–8. 10.1002/sim.4780090710
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/sim.4780090710</ArticleId>
            <ArticleId IdType="pubmed">2218183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hulsen T, de Vlieg J, Alkema W. BioVenn—A web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics. 2008; 9(1): 488. 10.1186/1471-2164-9-488
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2164-9-488</ArticleId>
            <ArticleId IdType="pmc">PMC2584113</ArticleId>
            <ArticleId IdType="pubmed">18925949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al.. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019; 47(D1): D607–D13. 10.1093/nar/gky1131
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId>
            <ArticleId IdType="pmc">PMC6323986</ArticleId>
            <ArticleId IdType="pubmed">30476243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The Gene Ontology Consortium. The gene ontology resource: 20 years and still GOing strong. Nucleic Acids Res. 2018; 47(D1): D330–D8. 10.1093/nar/gky1055
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gky1055</ArticleId>
            <ArticleId IdType="pmc">PMC6323945</ArticleId>
            <ArticleId IdType="pubmed">30395331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al.. Gene ontology: tool for the unification of biology. Nat Genet. 2000; 25(1): 25–9. 10.1038/75556
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/75556</ArticleId>
            <ArticleId IdType="pmc">PMC3037419</ArticleId>
            <ArticleId IdType="pubmed">10802651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al.. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 2003; 4(9): R60. 10.1186/gb-2003-4-9-r60</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/gb-2003-4-9-r60</ArticleId>
            <ArticleId IdType="pubmed">12734009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1): 44–57. 10.1038/nprot.2008.211
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nprot.2008.211</ArticleId>
            <ArticleId IdType="pubmed">19131956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37(1): 1–13. 10.1093/nar/gkn923
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkn923</ArticleId>
            <ArticleId IdType="pmc">PMC2615629</ArticleId>
            <ArticleId IdType="pubmed">19033363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000; 28(1): 27–30. 10.1093/nar/28.1.27
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/28.1.27</ArticleId>
            <ArticleId IdType="pmc">PMC102409</ArticleId>
            <ArticleId IdType="pubmed">10592173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flory J, Lipska K. Metformin in 2019. JAMA. 2019; 321(19): 1926–7. 10.1001/jama.2019.3805
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2019.3805</ArticleId>
            <ArticleId IdType="pmc">PMC7552083</ArticleId>
            <ArticleId IdType="pubmed">31009043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mallik R, Chowdhury TA. Metformin in cancer. Diabetes Res Clin Pract. 2018; 143: 409–19. 10.1016/j.diabres.2018.05.023
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.diabres.2018.05.023</ArticleId>
            <ArticleId IdType="pubmed">29807101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiang P, Shao Y, Sun YP, Zhang J, Chen LJ. Metformin inhibits proliferation and migration of endometrial cancer cells through regulating PI3K/AKT/MDM2 pathway. Eur Rev Med Pharmacol Sci. 2019; 23(4): 1778–85. 10.26355/eurrev_201902_17140
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.26355/eurrev_201902_17140</ArticleId>
            <ArticleId IdType="pubmed">30840303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schuiveling M, Vazirpanah N, Radstake T, Zimmermann M, Broen JCA. Metformin, a new era for an old drug in the treatment of immune mediated disease?
Curr Drug Targets. 2018; 19(8): 945–59. 10.2174/1389450118666170613081730
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1389450118666170613081730</ArticleId>
            <ArticleId IdType="pubmed">28606032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcucci F, Romeo E, Caserta CA, Rumio C, Lefoulon F. Context-dependent pharmacological effects of metformin on the immune system. Trends Pharmacol Sci. 2020; 41(3): 162–71. 10.1016/j.tips.2020.01.003
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2020.01.003</ArticleId>
            <ArticleId IdType="pubmed">32033771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang JC, An R, Jiang YQ, Yang J. Effects and mechanisms of metformin on the proliferation of esophageal cancer cells in vitro and in vivo. Cancer Res Treat. 2017; 49(3): 778–89. 10.4143/crt.2015.485
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4143/crt.2015.485</ArticleId>
            <ArticleId IdType="pmc">PMC5512357</ArticleId>
            <ArticleId IdType="pubmed">27857021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Zhang Y, Jia K, Dong Y, Ma W. Metformin inhibits the proliferation of A431 cells by modulating the PI3K/Akt signaling pathway. Exp Ther Med. 2015; 9(4): 1401–6. 10.3892/etm.2015.2220
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/etm.2015.2220</ArticleId>
            <ArticleId IdType="pmc">PMC4353749</ArticleId>
            <ArticleId IdType="pubmed">25780442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018; 14(11): 1483–96. 10.7150/ijbs.27173
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijbs.27173</ArticleId>
            <ArticleId IdType="pmc">PMC6158718</ArticleId>
            <ArticleId IdType="pubmed">30263000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gallagher EJ, Fierz Y, Vijayakumar A, Haddad N, Yakar S, LeRoith D. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia. Oncogene. 2012; 31(27): 3213–22. 10.1038/onc.2011.495
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2011.495</ArticleId>
            <ArticleId IdType="pmc">PMC3275680</ArticleId>
            <ArticleId IdType="pubmed">22037215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Świderska E, Strycharz J, Wróblewski A, Szemraj J, Drzewoski J, Śliwińska A. Role of PI3K/AKT pathway in insulin-mediated glucose uptake. In: Szablewski L, editor. Blood Glucose Levels. Vol. 1, 1st ed. London: IntechOpen; 2020. p. 1–18. 10.5772/intechopen.80402</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5772/intechopen.80402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu SC, Bassi DE, Zhang SY, Holoran D, Conti CJ, Klein-Szanto AJ. Overexpression of cyclin D2 is associated with increased in vivo invasiveness of human squamous carcinoma cells. Mol Carcinog. 2002; 34(3): 131–9. 10.1002/mc.10057
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.10057</ArticleId>
            <ArticleId IdType="pubmed">12112307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koyama-Nasu R, Nasu-Nishimura Y, Todo T, Ino Y, Saito N, Aburatani H, et al.. The critical role of cyclin D2 in cell cycle progression and tumorigenicity of glioblastoma stem cells. Oncogene. 2013; 32(33): 3840–5. 10.1038/onc.2012.399
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2012.399</ArticleId>
            <ArticleId IdType="pubmed">22964630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vences-Catalan F, Duault C, Kuo CC, Rajapaksa R, Levy R, Levy S. CD81 as a tumor target. Biochem Soc Trans. 2017; 45(2): 531–5. 10.1042/BST20160478
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BST20160478</ArticleId>
            <ArticleId IdType="pubmed">28408492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang N, Zuo L, Zheng H, Li G, Hu X. Increased expression of CD81 in breast cancer tissue is associated with reduced patient prognosis and increased cell migration and proliferation in MDA-MB-231 and MDA-MB-435S human breast cancer cell lines in vitro. Med Sci Monit. 2018; 24: 5739–47. 10.12659/MSM.911612
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12659/MSM.911612</ArticleId>
            <ArticleId IdType="pmc">PMC6109364</ArticleId>
            <ArticleId IdType="pubmed">30117494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung K-K, Liu X-W, Chirco R, Fridman R, Kim H-RC. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J. 2006; 25(17): 3934–42. 10.1038/sj.emboj.7601281
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.emboj.7601281</ArticleId>
            <ArticleId IdType="pmc">PMC1560352</ArticleId>
            <ArticleId IdType="pubmed">16917503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tugues S, Honjo S, König C, Padhan N, Kroon J, Gualandi L, et al.. Tetraspanin CD63 promotes vascular endothelial growth factor receptor 2-β1 integrin complex formation, thereby regulating activation and downstream signaling in endothelial cells in vitro and in vivo. J Biol Chem. 2013; 288(26): 19060–71. 10.1074/jbc.M113.468199
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M113.468199</ArticleId>
            <ArticleId IdType="pmc">PMC3696679</ArticleId>
            <ArticleId IdType="pubmed">23632027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Podojil JR, Miller SD. Potential targeting of B7-H4 for the treatment of cancer. Immunol Rev. 2017; 276(1): 40–51. 10.1111/imr.12530
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12530</ArticleId>
            <ArticleId IdType="pmc">PMC5630270</ArticleId>
            <ArticleId IdType="pubmed">28258701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang H, Li C, Ren G. Clinical significance of the B7-H4 as a novel prognostic marker in breast cancer. Gene. 2017; 623: 24–8. 10.1016/j.gene.2017.04.003
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2017.04.003</ArticleId>
            <ArticleId IdType="pubmed">28412458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian Y, Du Z, Xing Y, Zhou T, Chen T, Shi M. Interferon regulatory factor 4 (IRF4) is overexpressed in human non‑small cell lung cancer (NSCLC) and activates the Notch signaling pathway. Mol Med Rep. 2017; 16(5): 6034–40. 10.3892/mmr.2017.7319
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2017.7319</ArticleId>
            <ArticleId IdType="pmc">PMC5865806</ArticleId>
            <ArticleId IdType="pubmed">28849037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen K, Kolls JK. Interleukin-17A (IL17A). Gene. 2017; 614: 8–14. 10.1016/j.gene.2017.01.016
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2017.01.016</ArticleId>
            <ArticleId IdType="pmc">PMC5394985</ArticleId>
            <ArticleId IdType="pubmed">28122268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo N, Shen G, Zhang Y, Moustafa AA, Ge D, You Z. Interleukin-17 promotes migration and invasion of human cancer cells through upregulation of MTA1 expression. Front Oncol.
2019; 9: 546. 10.3389/fonc.2019.00546
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2019.00546</ArticleId>
            <ArticleId IdType="pmc">PMC6596356</ArticleId>
            <ArticleId IdType="pubmed">31281798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bent R, Moll L, Grabbe S, Bros M. Interleukin-1 beta—a friend or foe in malignancies?
Int J Mol Sci. 2018; 19(8): 2155. 10.3390/ijms19082155
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19082155</ArticleId>
            <ArticleId IdType="pmc">PMC6121377</ArticleId>
            <ArticleId IdType="pubmed">30042333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Litmanovich A, Khazim K, Cohen IR. The role of interleukin-1 in the pathogenesis of cancer and its potential as a therapeutic target in clinical practice. Oncol Ther. 2018; 6(2): 109–27. 10.1007/s40487-018-0089-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40487-018-0089-z</ArticleId>
            <ArticleId IdType="pmc">PMC7359982</ArticleId>
            <ArticleId IdType="pubmed">32700032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuhn DJ, Smith DM, Pross S, Whiteside TL, Dou QP. Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability. J Cell Biochem. 2003; 89(4): 824–36. 10.1002/jcb.10557
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.10557</ArticleId>
            <ArticleId IdType="pubmed">12858347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016; 5(6): e1163462. 10.1080/2162402X.2016.1163462
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2016.1163462</ArticleId>
            <ArticleId IdType="pmc">PMC4938354</ArticleId>
            <ArticleId IdType="pubmed">27471638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S, Hattori Y, et al.. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol. 2012; 188(2): 703–13. 10.4049/jimmunol.1101270
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1101270</ArticleId>
            <ArticleId IdType="pubmed">22174445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, et al.. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol. 2007; 178(7): 4222–9. 10.4049/jimmunol.178.7.4222
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.178.7.4222</ArticleId>
            <ArticleId IdType="pubmed">17371978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caruso JA, Akli S, Pageon L, Hunt KK, Keyomarsi K. The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. Oncogene. 2015; 34(27): 3556–67. 10.1038/onc.2014.284
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2014.284</ArticleId>
            <ArticleId IdType="pmc">PMC4362782</ArticleId>
            <ArticleId IdType="pubmed">25195861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, et al.. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2014; 16(6): 3417. 10.1186/s13058-014-0497-4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-014-0497-4</ArticleId>
            <ArticleId IdType="pmc">PMC4326485</ArticleId>
            <ArticleId IdType="pubmed">25551582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu KS, Lee Y, Kim CM, Park EC, Choi J, Lim DS, et al.. The protease inhibitor, elafin, induces p53-dependent apoptosis in human melanoma cells. Int J Cancer. 2010; 127(6): 1308–20. 10.1002/ijc.25125
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.25125</ArticleId>
            <ArticleId IdType="pubmed">20020498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilhelmsson U, Eliasson C, Bjerkvig R, Pekny M. Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression. Oncogene. 2003; 22(22): 3407–11. 10.1038/sj.onc.1206372
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1206372</ArticleId>
            <ArticleId IdType="pubmed">12776191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grottke A, Ewald F, Lange T, Nörz D, Herzberger C, Bach J, et al.. Downregulation of AKT3 increases migration and metastasis in triple negative breast cancer cells by upregulating S100A4. PLoS One. 2016; 11(1): e0146370. 10.1371/journal.pone.0146370
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0146370</ArticleId>
            <ArticleId IdType="pmc">PMC4704820</ArticleId>
            <ArticleId IdType="pubmed">26741489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phung TL, Du W, Xue Q, Ayyaswamy S, Gerald D, Antonello Z, et al.. AKT1 and AKT3 exert opposing roles in the regulation of vascular tumor growth. Cancer Res. 2015; 75(1): 40–50. 10.1158/0008-5472.CAN-13-2961
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-2961</ArticleId>
            <ArticleId IdType="pubmed">25388284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng S, Song J. Relationship of beta-glucuronidase to differentiation and invasion of human colorectal carcinoma. Chin Med J. 1999; 112(9): 854–7. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11717961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng S, Song JD. Determination of β-glucuronidase in human colorectal carcinoma cell lines. World J Gastroenterol. 1997; 3(4): 251–2. 10.3748/wjg.v3.i4.251
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v3.i4.251</ArticleId>
            <ArticleId IdType="pmc">PMC4806251</ArticleId>
            <ArticleId IdType="pubmed">27053883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sui H, Shi C, Yan Z, Wu M. Overexpression of cathepsin L is associated with chemoresistance and invasion of epithelial ovarian cancer. Oncotarget. 2016; 7(29): 45995–6001. 10.18632/oncotarget.10276
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.10276</ArticleId>
            <ArticleId IdType="pmc">PMC5216776</ArticleId>
            <ArticleId IdType="pubmed">27351223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Wang S, Wang Q, Yang Z, Pan Z, Li L. Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer. Oncol Rep. 2014; 31(3): 1334–42. 10.3892/or.2014.2967
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2014.2967</ArticleId>
            <ArticleId IdType="pubmed">24402045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P. Transferrin receptor 1 in cancer: a new sight for cancer therapy. Am J Cancer Res. 2018; 8(6): 916–31. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6048407</ArticleId>
            <ArticleId IdType="pubmed">30034931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Wang Y, Zhang J, Zhong J, Yang R. COL1A1 promotes metastasis in colorectal cancer by regulating the WNT/PCP pathway. Mol Med Rep. 2018; 17(4): 5037–42. 10.3892/mmr.2018.8533
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2018.8533</ArticleId>
            <ArticleId IdType="pmc">PMC5865965</ArticleId>
            <ArticleId IdType="pubmed">29393423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Shen JX, Wu HT, Li XL, Wen XF, Du CW, et al.. Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target. Discov Med. 2018; 25(139): 211–23. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29906404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piper AJ, Clark JL, Mercado-Matos J, Matthew-Onabanjo AN, Hsieh C-C, Akalin A, et al.. Insulin receptor substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC). PLoS One. 2019; 14(8): e0220567. 10.1371/journal.pone.0220567
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0220567</ArticleId>
            <ArticleId IdType="pmc">PMC6687170</ArticleId>
            <ArticleId IdType="pubmed">31393907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You HL, Liu TT, Weng SW, Chen CH, Wei YC, Eng HL, et al.. Association of IRS2 overexpression with disease progression in intrahepatic cholangiocarcinoma. Oncol Lett. 2018; 16(4): 5505–11. 10.3892/ol.2018.9284
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2018.9284</ArticleId>
            <ArticleId IdType="pmc">PMC6144925</ArticleId>
            <ArticleId IdType="pubmed">30250623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubota T, Inoue M, Kubota N, Takamoto I, Mineyama T, Iwayama K, et al.. Downregulation of macrophage Irs2 by hyperinsulinemia impairs IL-4-indeuced M2a-subtype macrophage activation in obesity. Nat Commun. 2018; 9(1): 4863. 10.1038/s41467-018-07358-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-07358-9</ArticleId>
            <ArticleId IdType="pmc">PMC6242852</ArticleId>
            <ArticleId IdType="pubmed">30451856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubota T, Kubota N, Kadowaki T. Imbalanced insulin actions in obesity and type 2 diabetes: key mouse models of insulin signaling pathway. Cell Metab. 2017; 25(4): 797–810. 10.1016/j.cmet.2017.03.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2017.03.004</ArticleId>
            <ArticleId IdType="pubmed">28380373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuroki M, Abe H, Imakiirei T, Liao S, Uchida H, Yamauchi Y, et al.. Identification and comparison of residues critical for cell-adhesion activities of two neutrophil CD66 antigens, CEACAM6 and CEACAM8. J Leukoc Biol. 2001; 70(4): 543–50. 10.1189/jlb.70.4.543
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.70.4.543</ArticleId>
            <ArticleId IdType="pubmed">11590190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horst AK, Wagener C. CEA-related CAMs. In: Behrens J, Nelson WJ, editors. Cell Adhesion. Handbook of Experimental Pharmacology. Vol. 165, 1st ed. Berlin: Springer; 2004. p. 283–341. 10.1007/978-3-540-68170-0_10
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-540-68170-0_10</ArticleId>
            <ArticleId IdType="pubmed">20455097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwabuchi E, Miki Y, Onodera Y, Shibahara Y, Takagi K, Suzuki T, et al.. Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells. Clin Exp Metastasis. 2019; 36(5): 423–32. 10.1007/s10585-019-09981-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10585-019-09981-2</ArticleId>
            <ArticleId IdType="pubmed">31222613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song M, Yin Y, Zhang J, Zhang B, Bian Z, Quan C, et al.. MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1. Protein Cell. 2014; 5(11): 851–61. 10.1007/s13238-014-0093-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13238-014-0093-5</ArticleId>
            <ArticleId IdType="pmc">PMC4225484</ArticleId>
            <ArticleId IdType="pubmed">25149074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Z, Zhang N, Zha L, Mao HC, Chen X, Xiang JF, et al.. Aberrant expression of the autocrine motility factor receptor correlates with poor prognosis and promotes metastasis in gastric carcinoma. Asian Pac J Cancer Prev. 2014; 15(2): 989–97. 10.7314/apjcp.2014.15.2.989
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7314/apjcp.2014.15.2.989</ArticleId>
            <ArticleId IdType="pubmed">24568530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang H, Li F, He C, Wang X, Li Q, Gao H. Expression of Gli1 and Wnt2B correlates with progression and clinical outcome of pancreatic cancer. Int J Clin Exp Pathol. 2014; 7(7): 4531–8. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4129084</ArticleId>
            <ArticleId IdType="pubmed">25120849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katoh M.
WNT2B: comparative integromics and clinical applications. Int J Mol Med. 2005; 16(6): 1103–8. 10.3892/ijmm.16.6.1103
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.16.6.1103</ArticleId>
            <ArticleId IdType="pubmed">16273293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Yu X, Yang L. MiR-145 inhibits cervical cancer progression and metastasis by targeting WNT2B by Wnt/β-catenin pathway. Int J Clin Exp Pathol. 2019; 12(10): 3740–51. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6949761</ArticleId>
            <ArticleId IdType="pubmed">31933762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma H, Cai H, Zhang Y, Wu J, Liu X, Zuo J, et al.. Membrane palmitoylated protein 3 promotes hepatocellular carcinoma cell migration and invasion via up-regulating matrix metalloproteinase 1. Cancer Lett. 2014; 344(1): 74–81. 10.1016/j.canlet.2013.10.017
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2013.10.017</ArticleId>
            <ArticleId IdType="pubmed">24513266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bill CA, Vines CM. Phospholipase C. In: Islam S, editor. Calcium Signaling. Advances in Experimental Medicine and Biology. Vol. 1131, 2nd ed. Cham: Springer Nature Switzerland; 2019. p. 215–42. 10.1007/978-3-030-12457-1_9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-030-12457-1_9</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stanislaus A, Bakhtiar A, Salleh D, Tiash S, Fatemian T, Hossain S, et al.. Knockdown of PLC-gamma-2 and calmodulin 1 genes sensitizes human cervical adenocarcinoma cells to doxorubicin and paclitaxel. Cancer Cell Int. 2012; 12(1): 30. 10.1186/1475-2867-12-30
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1475-2867-12-30</ArticleId>
            <ArticleId IdType="pmc">PMC3407783</ArticleId>
            <ArticleId IdType="pubmed">22709569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma D, Lian F, Wang X. PLCG2 promotes hepatocyte proliferation in vitro via NF-κB and ERK pathway by targeting bcl2, myc and ccnd1. Artif Cells Nanomed Biotechnol. 2019; 47(1): 3786–92. 10.1080/21691401.2019.1669616
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21691401.2019.1669616</ArticleId>
            <ArticleId IdType="pubmed">31549850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng B, Zhou M, Wu HT, Xiong Z. SPP1 promotes ovarian cancer progression via integrin β1/FAK/AKT signaling pathway. OncoTargets and Therapy. 2018; 11: 1333–43. 10.2147/OTT.S154215
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S154215</ArticleId>
            <ArticleId IdType="pmc">PMC5856063</ArticleId>
            <ArticleId IdType="pubmed">29559792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamort A-S, Giopanou I, Psallidas I, Stathopoulos GT. Osteopontin as a link between inflammation and cancer: the thorax in the spotlight. Cells. 2019; 8(8): 815. 10.3390/cells8080815
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8080815</ArticleId>
            <ArticleId IdType="pmc">PMC6721491</ArticleId>
            <ArticleId IdType="pubmed">31382483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pietilä M, Sahgal P, Peuhu E, Jäntti NZ, Paatero I, Närvä E, et al.. SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nat Commun. 2019; 10(1): 2340. 10.1038/s41467-019-10275-0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-10275-0</ArticleId>
            <ArticleId IdType="pmc">PMC6538630</ArticleId>
            <ArticleId IdType="pubmed">31138794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013; 273(2): 114–27. 10.1111/joim.12019
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/joim.12019</ArticleId>
            <ArticleId IdType="pubmed">23216836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng F-C, Zeng M-Q, Huang L, Li Y-L, Gao B-M, Chen J-J, et al.. Downregulation of VEGFA inhibits proliferation, promotes apoptosis, and suppresses migration and invasion of renal clear cell carcinoma. OncoTargets and Therapy. 2016; 9: 2131–41. 10.2147/OTT.S98002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S98002</ArticleId>
            <ArticleId IdType="pmc">PMC4835130</ArticleId>
            <ArticleId IdType="pubmed">27110129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menges CW, Altomare DA, Testa JR. FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis. Cell Cycle. 2009; 8(16): 2528–34. 10.4161/cc.8.16.9280
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.8.16.9280</ArticleId>
            <ArticleId IdType="pmc">PMC2739729</ArticleId>
            <ArticleId IdType="pubmed">19597341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu AQ, Xie Z, Chen XN, Feng J, Chen JW, Qin FJ, et al.. Fas-associated factor 1 inhibits tumor growth by suppressing Helicobacter pylori-induced activation of NF-κB signaling in human gastric carcinoma. Oncotarget. 2017; 8(5): 7999–8009. 10.18632/oncotarget.14033
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.14033</ArticleId>
            <ArticleId IdType="pmc">PMC5352377</ArticleId>
            <ArticleId IdType="pubmed">28030825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA. 2003; 100(15): 8933–8. 10.1073/pnas.1537685100
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1537685100</ArticleId>
            <ArticleId IdType="pmc">PMC166416</ArticleId>
            <ArticleId IdType="pubmed">12853564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saito S, Yamamoto H, Mukaisho K-I, Sato S, Higo T, Hattori T, et al.. Mechanisms underlying cancer progression caused by ezrin overexpression in tongue squamous cell carcinoma. PLoS One. 2013; 8(1): e54881. 10.1371/journal.pone.0054881
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0054881</ArticleId>
            <ArticleId IdType="pmc">PMC3554659</ArticleId>
            <ArticleId IdType="pubmed">23357878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med. 2004; 10(5): 201–4. 10.1016/j.molmed.2004.03.001
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2004.03.001</ArticleId>
            <ArticleId IdType="pubmed">15121044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schimmöller F, Díaz E, Mühlbauer B, Pfeffer SR. Characterization of a 76 kDa endosomal, multispanning membrane protein that is highly conserved throughout evolution. Gene. 1998; 216(2): 311–8. 10.1016/s0378-1119(98)00349-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0378-1119(98)00349-7</ArticleId>
            <ArticleId IdType="pubmed">9729438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark CR, Maile M, Blaney P, Hellweg SR, Strauss A, Durose W, et al.. Transposon mutagenesis screen in mice identifies TM9SF2 as a novel colorectal cancer oncogene. Sci Rep. 2018; 8(1): 15327. 10.1038/s41598-018-33527-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-33527-3</ArticleId>
            <ArticleId IdType="pmc">PMC6193042</ArticleId>
            <ArticleId IdType="pubmed">30333512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abou-Sharieha S, Sugii Y, Tuoya, Yu D, Chen L, Tokutaka H, et al.. Identification of TM9SF2 as a candidate of the cell surface marker common to breast carcinoma cells. Chin J Clin Oncol. 2009; 6: 1. 10.1007/s11805-009-0001-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11805-009-0001-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han X, Guo B, Li Y, Zhu B. Tissue factor in tumor microenvironment: a systematic review. J Hematol Oncol. 2014; 7: 54. 10.1186/s13045-014-0054-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-014-0054-8</ArticleId>
            <ArticleId IdType="pmc">PMC4237870</ArticleId>
            <ArticleId IdType="pubmed">25084809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White NMA, Masui O, Newsted D, Scorilas A, Romaschin AD, Bjarnason GA, et al.. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. Br J Cancer. 2014; 110(5): 1250–9. 10.1038/bjc.2013.828
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2013.828</ArticleId>
            <ArticleId IdType="pmc">PMC3950857</ArticleId>
            <ArticleId IdType="pubmed">24496460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J-M, Tseng C-W, Lin C-C, Law C-H, Chien Y-A, Kuo W-H, et al.. Upregulation of LGALS1 is associated with oral cancer metastasis. Ther Adv Med Oncol. 2018; 10: 1–20. 10.1177/1758835918794622
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1758835918794622</ArticleId>
            <ArticleId IdType="pmc">PMC6109855</ArticleId>
            <ArticleId IdType="pubmed">30159048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao Z-W, Dong K, Zhang H-Z. The roles of CD73 in cancer. Biomed Res Int. 2014; 2014: 460654. 10.1155/2014/460654
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/460654</ArticleId>
            <ArticleId IdType="pmc">PMC4121992</ArticleId>
            <ArticleId IdType="pubmed">25126561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilder AS, Natali L, Van Dyk DM, Zalfa C, Banki MA, Pizzo DP, et al.. The urokinase receptor induces a mesenchymal gene expression signature in glioblastoma cells and promotes tumor cell survival in neurospheres. Sci Rep. 2018; 8(1): 2982. 10.1038/s41598-018-21358-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-21358-1</ArticleId>
            <ArticleId IdType="pmc">PMC5813209</ArticleId>
            <ArticleId IdType="pubmed">29445239</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
